Combination Therapy with Adalimumab Plus Intensive Granulocyte and Monocyte Adsorptive Apheresis Induced Clinical Remission in a Crohn's Disease Patient with the Loss of Response to Scheduled Adalimumab Maintenance Therapy: A Case Report

被引：8
|
作者：
Ozeki, Keiji [1 ]
Tanida, Satoshi [1 ]
Mizushima, Takashi [2 ]
Mizoshita, Tsutomu [1 ]
Tsukamoto, Hironobu [1 ]
Hirata, Yoshikazu [1 ]
Murakami, Kenji [1 ]
Shimura, Takaya [1 ]
Kataoka, Hiromi [1 ]
Kamiya, Takeshi [1 ]
Joh, Takashi [1 ]
机构：
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Gastroenterol & Metab, Nagoya, Aichi, Japan
[2] Gifu Prefectural Tajimi Hosp, Gifu, Japan
来源：
INTERNAL MEDICINE | 2012年 / 51卷 / 06期
关键词：
refractory Crohn's disease; adalimumab; intensive granulocyte/monocyte adsorptive apheresis; anti-adalimumab antibody; clinical remission; INFLAMMATORY-BOWEL-DISEASE; ULCERATIVE-COLITIS; NECROSIS-FACTOR; TRIAL; MULTICENTER; INFECTION;
D O I：
10.2169/internalmedicine.51.6801
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
A 21-year-old Caucasian man with a diagnosis of Crohn's disease (CD) at the age of 14 was admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) maintenance therapy. His symptoms remained virtually unchanged following high dose corticosteroid therapy. Seven days later, combination therapy with ADA plus intensive granulocyte/monocyte adsorptive apheresis (GMA) was initiated, which induced clinical remission. Therefore, combination therapy with ADA plus intensive GMA appears to be an effective therapeutic option for patients with severe CD while under scheduled ADA maintenance therapy.
引用
收藏
页码：595 / 599
页数：5
相关论文
共 50 条
  • [21] Adsorptive granulocyte and monocyte apheresis therapy for refractory Crohn's disease: An open multicentre prospective study
    Fukuda, Y
    Matsui, T
    Suzuki, Y
    Kanke, K
    Matsumoto, T
    Takazoe, M
    Matsumoto, T
    Motoya, S
    Honma, T
    Sawada, K
    Fukunaga, K
    Yao, T
    Shimoyama, T
    Hibi, T
    GASTROENTEROLOGY, 2004, 126 (04) : A630 - A630
  • [22] A Case of Molluscum Contagiosum Infection in a Patient with Crohn's Disease, Receiving Combination Therapy with Azathioprine and Adalimumab
    Cintolo, Marcello
    Guarneri, Claudio
    Lentini, Maria
    JOURNAL OF CROHNS & COLITIS, 2015, 9 (07): : 593 - 594
  • [23] Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission
    Plevris, Nikolas
    Lyons, Mathew
    Jenkinson, Philip W.
    Chuah, Cher S.
    Merchant, Lynne M.
    Pattenden, Rebecca J.
    Watson, Eleanor F.
    Ho, Gwo-Tzer
    Noble, Colin L.
    Shand, Alan G.
    Din, Shahida
    Arnott, Ian D.
    Jones, Gareth R.
    Lees, Charlie W.
    INFLAMMATORY BOWEL DISEASES, 2019, 25 (06) : 1036 - 1043
  • [24] Osteonecrosis of the jaw in a Crohn’s disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report
    Raimund HM Preidl
    Tobias Ebker
    Martin Raithel
    Falk Wehrhan
    Friedrich W Neukam
    Philipp Stockmann
    BMC Gastroenterology, 14
  • [25] Osteonecrosis of the jaw in a Crohn's disease patient following a course of Bisphosphonate and Adalimumab therapy: a case report
    Preidl, Raimund H. M.
    Ebker, Tobias
    Raithel, Martin
    Wehrhan, Falk
    Neukam, Friedrich W.
    Stockmann, Philipp
    BMC GASTROENTEROLOGY, 2014, 14
  • [26] Trough levels of adalimumab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn's disease on adalimumab maintenance therapy
    Oh, E. H.
    Yoon, A. -R.
    Park, S. H.
    Kim, J.
    Ham, N.
    Song, E. M.
    Hwang, S. W.
    Park, S. H.
    Yang, D. -H.
    Byeon, J. -S.
    Myung, S. -J.
    Yang, S. -K.
    Ye, B. D.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S260 - S261
  • [27] Systematic Review and Meta-analysis: Adalimumab Monotherapy Versus Combination Therapy with Immunomodulators for Induction and Maintenance of Remission and Response in Patients with Crohn's Disease
    Chalhoub, Jean M.
    Rimmani, Hussein H.
    Gumaste, Vivek V.
    Sharara, Ala I.
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (08) : 316 - 327
  • [28] Systematic Review and Meta-Analysis: Adalimumab Monotherapy versus Combination Therapy With Immunomodulators for Induction and Maintenance of Remission and Response in Patients With Crohn's Disease
    Chalhoub, Jean M.
    Rimmani, Hussein
    Gumaste, Vivek
    Sharara, Ala
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S328 - S328
  • [29] ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN'S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
    Vazharov, Ivaylo
    Bozov, Hristo
    Zlateva, Snezha
    Bonchev, Georgi
    JOURNAL OF IMAB, 2016, 22 (04): : 1389 - 1391
  • [30] Adalimumab sustains clinical remission and overall clinical benefit after 2 years of therapy for Crohn's disease
    Panaccione, R.
    Colombel, J. -F.
    Sandborn, W. J.
    Rutgeerts, P.
    D'Haens, G. R.
    Robinson, A. M.
    Chao, J.
    Mulani, P. M.
    Pollack, P. F.
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2010, 31 (12) : 1296 - 1309
12345